Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile

Chemotherapy

Volumn 53, Issue 4, 2007, Pages 267-274

  Odenholt, Inga ^a,c   Walder, Mats ^b   Wullt, Marlene ^a  

^a Department of Clinical Sciences   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Clostridium difficile; Fusidic acid; Metronidazole; Pharmacodynamic effect; Postantibiotic effect; Postantibiotic sub MIC effect; Vancomycin

Indexed keywords

FUSIDIC ACID; METRONIDAZOLE; VANCOMYCIN;

ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DOSE-RESPONSE RELATIONSHIP, DRUG; FUSIDIC ACID; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN;

EID: 34447513074     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104471     Document Type: Article

References (37)

1. Craig WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing in mice and men. Clin Infect Dis 1998;26:1-12.
2. Drusano GL, Johnson DE, Rosen M, Standiford HC: Pharmacodynamics of a fluoroquinolone antimicrobial agents in a neutropenic rat model of pseudomonas sepsis. Antimicrob Agents Chemother 1993;37:483-490.
3. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-1081.
4. Gilbert DN: Meta-analysis are no longer required for determining the efficacy of single daily dosing of aminoglycosides. Clin Infect Dis 1997;24:816-819.
5. Odenholt I, Holm S, Cars O: An in vivo model for evaluation of the postantibiotic effect. Scand J Infect Dis 1988;20:97-103.
6. Craig WA, Gudmundsson S: The postantibiotic effect; in Lorian V (ed): Antibiotics in Laboratory Medicine, ed 4. Baltimore, Williams & Wilkins, 1996, pp 296-329.
7. Odenholt I, Holm S, Cars O: Effects of supra and sub-MIC benzylpenicillin concentrations on group A beta-hemolytic streptococci during the postantibiotic phase in vivo. J Antimicrob Chemother 1990;26:193-201.
8. Odenholt-Tornqvist I, Löwdin E, Cars O: Pharmacodynamic effects of subinhibitory concentrations in vitro. Antimicrob Agents Chemother 1991;35:1834-1839.
9. Odenholt-Tornqvist I, Löwdin E, Cars O: Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin. Antimicrob Agents Chemother 1992;36:1852-1858.
10. Odenholt-Tornqvist I: Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem. J Antimicrob Chemother 1993;31:881-892.
11. Cars O, Odenholt-Tornqvist I: The post-antibiotic sub-MIC effect in vitro and in vivo. J Antimicrob Chemother 1993;31(suppl D):159-166.
12. Odenholt-Tornqvist I, Löwdin E, Cars O: Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin and azithromycin on respiratory tract pathogens. Antimicrob Agents Chemother 1995;39:221-226.
13. Licata L, Smith CE, Goldschmidt RM, Barrett JF, Frosco M: Comparison of the postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 1997;41:950-955.
14. Wilcox MH: Clostridium difficile infection and pseudomembranous colitis. Best Pract Res Clin Gastroenterol 2003;17:475-493.
15. Cartmill TD, Shrimpton SB, Panigrahi H, Khanna V, Brown R, Poxton IR: Nosocomial diarrhoea due to a single strain of Clostridium difficile: a prolonged outbreak in elderly patients. Age Ageing 1992;21:245-249.
16. Testore GP, Pantosti A, Cerquetti M, Babudieri S, Panichi G, Gianfrilli PM: Evidence for cross-infection in an outbreak of Clostridium difficile-associated diarrhoea in a surgical unit. J Med Microbiol 1988;26:125-128.
17. McFarland LV, Mulligan ME, Kwok RY, Stamm WE: Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204-210.
18. Barbut F, Corthier G, Charpak Y, Cerf M, Monteil H, Foss T, Trevoux A, De Barbeyrac B, Boussougant Y, Tigaud S, Tytgat F, Sedallian A, Duborgel S, Collignon A, Le Guern ME, Bernasconi P, Petit JC: Prevalence and pathogenicity of Clostridium difficile in hospitalised patients. A French multicenter study. Arch Intern Med 1996;156:1449-1454.
19. Wilcox MH, Howe R: Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995;36:673-679.
20. Gerding DN: Treatment of Clostridium difficile-associated diarrhea and colitis. Curr Top Microbiol Immunol 2000;250:127-139.
21. Gerding DN: Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin Infect Dis 1997;25(suppl 2):206-210.
22. Barbut F, Decre D, Burghoffer B, Lesage D, Delisle F, Lalande V, Delmée M, Avesani V, Sano N, Coudert C, Petit J-C: Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 1999;43:2607-2611.
23. Wong SS, Woo PC, Luk WK, Yuen KY: Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 1999;34:1-6.
24. Brazier JS, Fawley W, Freeman J, Wilcox MH: Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 2001;48:741-742.
25. Pelaez T, Alcala L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz JM, Bouza E: Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002;46:1647-1650.
26. Collignon P, Turnidge J: Fusidic acid in vitro activity. Int J Antimicrob Agents 1999;12(suppl 2):45-58.
27. Wullt M, Odenholt I: A double-blind randomised controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 2004;54:211-216.
28. National Committee for Clinical Laboratory Standards: Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Approved Standard, ed 5. NCCLS document M11-A5. Wayne, National Committee for Clinical Laboratory Standards, 2003.
29. Levett PN: Time-dependent killing of Clostridium difficile by metronidazole and vancomycin. J Antimicrob Chemother 1991;27:55-62.
30. Löwdin E, Odenholt I, Cars O: In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis . Antimicrob Agents Chemother 1998;42:2739-2744.
31. Godtfredsen W, Roholt K, Tybring L: Fucidin: a new orally active antibiotic. Lancet 1962;i:928-931.
32. Munckhof WJ, Turnidge JD: The postantibiotic effect of fusidic acid against Gram-positive bacteria. J Antimicrob Chemother 1997;40:433-436.
33. 2 generation. Clin Microbiol Infect 1997;3:82-88.
34. Bolton RP, Culshaw MA: Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986;27:1169-1172.
35. Fekety R: Vancomycin and teichoplanin; in Mandell GL, Bennet JE, Dolin R (eds): Mandell, Douglas and Bennet's Principles and Practice of Infectious Diseases. New York, Churchill Livingstone, 1995, pp 346-354.
36. Small PM, Chambers HF: Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990;34:1227-1231.
37. Reeves DS: The pharmacokinetics of fusidic acid. J Antimicrob Chemother 1987;20:467-476.